NCM Capital Management LLC Purchases 756 Shares of Eli Lilly and Company (NYSE:LLY)

NCM Capital Management LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 37.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,786 shares of the company's stock after acquiring an additional 756 shares during the quarter. Eli Lilly and Company makes up approximately 1.0% of NCM Capital Management LLC's holdings, making the stock its 18th largest holding. NCM Capital Management LLC's holdings in Eli Lilly and Company were worth $2,151,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of LLY. Royal Capital Wealth Management LLC increased its position in Eli Lilly and Company by 0.4% in the 4th quarter. Royal Capital Wealth Management LLC now owns 3,634 shares of the company's stock valued at $2,805,000 after acquiring an additional 15 shares in the last quarter. Glen Eagle Advisors LLC increased its holdings in shares of Eli Lilly and Company by 0.6% in the fourth quarter. Glen Eagle Advisors LLC now owns 3,499 shares of the company's stock valued at $2,701,000 after purchasing an additional 20 shares in the last quarter. Mpwm Advisory Solutions LLC bought a new position in Eli Lilly and Company in the 4th quarter worth approximately $188,000. Delta Investment Management LLC lifted its holdings in Eli Lilly and Company by 32.2% during the 4th quarter. Delta Investment Management LLC now owns 2,293 shares of the company's stock worth $1,770,000 after buying an additional 559 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Eli Lilly and Company by 15.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,084,880 shares of the company's stock valued at $5,469,527,000 after buying an additional 969,376 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $745.72 on Wednesday. The firm has a fifty day simple moving average of $795.44 and a 200 day simple moving average of $804.82. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The stock has a market capitalization of $706.75 billion, a price-to-earnings ratio of 63.68, a PEG ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business's revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.58 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's payout ratio is currently 48.82%.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.13% of the company's stock.

Analysts Set New Price Targets

LLY has been the subject of a number of recent research reports. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, UBS Group cut their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.